产品号 #78036_C
白介素2
总览
白介素 2 (IL-2) 是一种单体细胞因子，最初被鉴定为 T 细胞生长因子 (Gaffen & Liu)。它与由 CD25、CD122 和 CD132 组成的异源三聚体受体结合。结合后，它会激活 JAK3、STAT5 和 AKT 依赖性信号通路，从而导致细胞增殖和存活 (Ma et al.)。大部分 IL-2 由活化的 CD4+ 和 CD8+ T 细胞分泌，尽管 B 细胞和树突状细胞也少量产生 IL-2。IL-2 下调免疫反应以防止胸腺发育过程中的自身免疫，影响 CD4+CD25+ 调节性 T 细胞的发育，并影响滤泡辅助性 T 细胞的发育。IL-2 还通过抑制 Th17 分化来控制炎症 (Banchereau et al.)。血清中高水平的 IL-2 与硬皮病、类风湿性关节炎以及胃癌和非小细胞肺癌的进展有关，尽管没有已知疾病可以直接归因于 IL-2 的缺乏或过量（Gaffen & Liu）。
亚型
细胞因子
细胞类型
造血干/祖细胞，NK 细胞，T 细胞，T 细胞，CD4+，T 细胞，CD8+
种属
人
研究领域
免疫，干细胞生物学
纯度
≥ 95 %
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (3)
Publications (1)
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nature medicine 2018 OCT
Abstract
Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) receptor, is a powerful anticancer approach. However, many patients do not respond to checkpoint blockade. Tumor PD-L1 expression is a potential efficacy biomarker, but the complex mechanisms underlying its regulation are not completely understood. Here, we show that the eukaryotic translation initiation complex, eIF4F, which binds the 5' cap of mRNAs, regulates the surface expression of interferon-$\gamma$-induced PD-L1 on cancer cells by regulating translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor. eIF4F complex formation correlates with response to immunotherapy in human melanoma. Pharmacological inhibition of eIF4A, the RNA helicase component of eIF4F, elicits powerful antitumor immune-mediated effects via PD-L1 downregulation. Thus, eIF4A inhibitors, in development as anticancer drugs, may also act as cancer immunotherapies.
更多信息
| Species | Human |
|---|---|
| Purity | ≥ 95% |
相关产品
-
ImmunoCult™ 人CD3/CD28 T细胞激活剂人T细胞激活扩增试剂
-
ImmunoCult™ XF 人T细胞扩增培养基用于T细胞扩增的无血清和无异种成分培养基
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
